NASDAQ$NUTX
Nutex Health Inc · Q1 2026 earnings
Q1 2026 earnings ·
Briefing
Nutex Health reported Q1 2026 revenue of $216.5M and net income of $62.8M, with diluted EPS of $6.52.
For Q1 2026, Nutex Health reported revenue of $216.5M and net income of $62.8M. The 10-Q discusses segment performance, costs, and liquidity in MD&A.
- Revenue of $216.5M for Q1 2026.
- Net income of $62.8M; diluted EPS $6.52.
- Operating trends and segment mix are detailed in the quarterly report.
- Liquidity, capital allocation, and macro exposure are discussed in MD&A.
Headline financials
Revenue & EPS history
Nutex Health Inc · Revenue · Quarterly
$216M
Revenue by segment
Nutex Health Inc · $244M total across 2 segments · Q2 2025
- Hospital Division$236M—96.9%
- Population Health Management$7.68M—3.1%
Forward guidance
The 10-Q does not provide numeric consolidated annual EPS guidance for Nutex Health. MD&A covers costs, capital, and sector-specific risks.
Tailwinds
- Management discusses operational priorities and liquidity in the filing.
- Segment or product trends are disclosed where applicable.
Headwinds
- Macro, input-cost, and interest-rate exposure can affect near-term results.
- One-time items may distort quarterly comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q1 2026
+1.9%
Avg return
Earnings day
+17.2%
Avg return
5 days after
+21.1%
Avg return
30 days after
62%
8 / 13 earnings
Positive
+22.4%
Q1 2022
Best reaction
-14.3%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +6.4% | +8.0% | +14.4% | |
| Q4 2025 | -14.3% | -14.1% | -4.2% | |
| Q3 2025 | +0.0% | +32.9% | +64.1% | |
| Q1 2025 | +1.0% | +40.2% | +0.2% | |
| Q3 2024 | +6.3% | +38.2% | +39.3% | |
| Q2 2024 | +0.9% | +62.7% | +173.1% | |
| Q1 2024 | +6.2% | +14.8% | +0.7% | |
| Q3 2023 | +0.0% | -6.0% | -22.8% | |
| Q2 2023 | +3.6% | +0.9% | -20.1% | |
| Q1 2023 | +8.9% | +10.3% | -17.8% | |
| Q3 2022 | -9.2% | +1.7% | +59.7% | |
| Q2 2022 | -8.2% | -27.9% | -53.8% | |
| Q1 2022 | +22.4% | +61.8% | +41.2% | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro